Company intelligence / Profile preview

Milestone Holdings

Montreal, Quebec, Canada

Ownership: Private
Employees: ~33
Development stage: Other

Overview

Milestone received FDA approval for Cardamyst (etripamil) in December 2024 for acute symptomatic PSVT episodes. The Phase III RAPID study showed 64% of patients converted to sinus rhythm within 30 minutes versus 31% on placebo, with median onset of 17 minutes versus 54 minutes for placebo. Cardamyst is the first novel approved treatment for PSVT in more than 30 years.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Milestone Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Milestone Holdings.

Explore the full profile